Larimar Therapeutics, Inc. (LRMR)
2025-06-30 | ||||
|---|---|---|---|---|
| Research and development | 23,368 | |||
| General and administrative | 4,424 | |||
| Total operating expenses | 27,792 | |||
| Loss from operations | -27,792 | |||
| Other income, net | 1,610 | |||
| Net loss | -26,182 | |||
| Earnings per share, basic, total | -0.41 | |||
| Net loss per share, diluted | -0.41 | |||
| Weighted average common shares outstanding, diluted | 64,027,892 | |||
| Weighted average number of shares outstanding, basic, total | 64,027,892 | |||